Shanghai RAAS executives plan RMB 6m share buyback

Shanghai RAAS Blood Products announced that its vice chairman and general manager Jun Xu, along with seven other senior executives, plan to acquire additional company shares. The aggregate value of the planned acquisition is not less than RMB 6 million, sourced from their personal funds. This move aims to bolster investor confidence amid current capital market conditions.

The share increase plan, to be executed via centralized bidding transactions, will commence within six months from the announcement date. While no specific price range has been set, the executives will make acquisition decisions based on their assessment of the company's stock value.

This initiative is a personal decision by the executives. The company confirms that the plan complies with all relevant laws and regulations and will not alter the company's equity distribution or control structure. The executives have committed to not reducing their shareholdings or engaging in insider trading during the acquisition period.